1 / 25

A Revolution in Mind

A Revolution in Mind. Corporate Presentation July 2014. CSNX: HSM. Disclaimer.

liuz
Download Presentation

A Revolution in Mind

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A Revolution in Mind Corporate Presentation July 2014 CSNX: HSM

  2. Disclaimer This presentation contains certain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from Helius Medical Technologies expectations and projections. The Ontario Securities Commission has neither approved nor disapproved the information contained in this presentation. Except for statements of historical fact relating to the Company, certain information contained herein constitutes "forward-looking statements". Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. These factors include the inherent risks involved in the development of medical devices and FDA or other international regulatory agencies, product obsolescence, the uncertainties involved in patent defense and complexities and timelines associated with medical device product approvals in multiple jurisdictions. The possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. Circumstances or management's estimates or opinions could change. The reader is cautioned not to place undue reliance on forward-looking statements. 1 www.heliusmedical.com | CSNX: HSM

  3. Overview Helius Medical Technologies Inc. is a medical device holding company, enabling technologies with the potential to heal us. The company is targeting vastly underserved markets with a ground breaking device to significantly enhance the body’s ability to heal itself. • The company’s initial asset is The PoNS™ Device • PoNS treats Neurological Symptoms caused by disease or trauma • The PoNS™ Device has numerous potential medical indications; tested for MS, Stroke, Tinnitus... • Existing TBI treatments largely ineffective: > 35 years since new treatments • Sizeable scope for treatment; ~660k US military TBI sufferers, 5.3M living with TBI related disability. • US armed forces committed ~$30+M (non-dilutive) to advance to FDA approval • Testing and studies, to date, provide encouraging indications • Potential FDA approval anticipated by Q3, 2016 2 www.heliusmedical.com | CSNX: HSM

  4. Capital Structure & Financial Information Financial Overview: • $7.2 million investment ($3M from NIH, $4.1 private non dilutive donations) • $6.9 million from concurrent financing with new listing • $7.0 million Total in treasury post listing on CSE • Non Dilutive Commitment: US Army • $18.5M est. for development of registration trial and regulatory submission. • $20.0M est. for development of further indications (Tinnitus, PTSD, Sleep Improvement, Pain Management) 3 www.heliusmedical.com | CSNX: HSM

  5. Cranial Nerve Non-Invasive Neuromodulation The PoNS™Device Next Generation Device (Jun 2014) “Amplifying the body’s ability to heal itself” 5 www.heliusmedical.com | CSNX: HSM

  6. Important Core Concept - Neuroplasticity • Neuroplasticity describes the ability of the brain to remain “plastic” • The PoNS Device provides stimulation to the brain-stem and other brain structures via the cranial nerves • This stimulation when combined with a “task” (physical, cognitive or mental exercises) • seems to amplifies the brains self recovery mechanism • reinforces new learning • “re-engage” existing neural networks. • Multiple disease symptoms appear to be improved. 6 www.heliusmedical.com | CSNX: HSM

  7. PoNS 4.0 Device 7 www.heliusmedical.com | CSNX: HSM

  8. MS Example: A Spectrum of Symptoms Multiple Sclerosis Impact Scale (MSIS-29) Confidence Concentration Impatience Psycho-Social Anxiety Worry about MS Mental Fatigue Sleep Wellbeing Bladder/Bowel Control Spontaneity Slowness Self Transport Limits on Work Physical Using Hands Limits on Mobility Limits on Socializing Depending on Others Uncoordinated Spasms in Limbs Tremors Heavy Limbs Stiffness Clumsiness Moving Indoors Balance Carry Things Grip Clinically Significant Physical Tasks Extreme Not at All Severity of Symptoms 8 www.heliusmedical.com | CSNX: HSM

  9. * p < 0.05 ** p < 0.01 *** p < 0.005 DGI change Weeks Two groups (10 each): • “Active” PoNS + exercises • “Control” PoNS + exercises “Control” PoNS = no electrical stimulus Example Data: 20 Patient Multiple Sclerosis Pilot Study 12 wks home 4 wks home Study entry 8 wks home 2 wks lab Clinically significant Mean DGI 10 Active 10 Control 9 www.heliusmedical.com | CSNX: HSM

  10. Example Data : TBI – 4 Patient Pilot study ▲=5.0 Clinically Significant Change SOT Points Four female subjects, mean 48.3 y/0 Moderate, close-head non-penetrating, concussive TBI 9-11 Glasgow Coma Scale • SENSORY ORGANIZATION TEST (SOT) 10 www.heliusmedical.com | CSNX: HSM

  11. First Indication: Concussive Traumatic Brain Injury (TBI) Military • US: 2010-2012 – 100,000+ cases • 28% of patients at Walter-Reed >$100,000,000/year • Explosive blast injury, Overpressure, Penetrating injury, Diffuse axonal injury $76.5B Cost to US 30% Chronic Disability Civilian • Blunt trauma • MVAs • Sports • Assaults 60,000 Active Duty Soldiers TBI 600,000 Retired Soldiers TBI 5.3M living with TBI related disability 1.750 TBI/ year 30% chronic disability 11 www.heliusmedical.com | CSNX: HSM

  12. Existing TBI Treatment Largely Ineffective • “Treatment plan” involves rehabilitation efforts to teach patients how to cope with their specific injury-related symptoms. • Non-responsive TBI patients have no treatment protocol • All single therapy development has failed in multicenter clinical trials • In last 35 years no new treatment for TBI have been suggested or brought forward. • This is an underserved market with high morbidity associated cost burden….a fact well appreciated by the US Army. 12 www.heliusmedical.com | CSNX: HSM

  13. US Army Sponsored Registration Plan • Seeking a de-novo clearance from the FDA for the treatment of Balance disorder related to mild to moderate TBI…..study primary endpoint is improvement in balance. • Confirmed as Class II, non-significant risk, device. • Collaborative Research and Development Agreement (CRADA) with the US Armed Forces • Armed forces will be providing the facilities and personnel to perform the registrational clinical trials in Balance Disorder • Providing regulatory expertise and access to special regulatory relationship with the FDA • Committed to funding additional clinical trials estimated commitment in money and services $30M+ • Research collaboration agreement signed 1/22/2013 13 www.heliusmedical.com | CSNX: HSM

  14. Milestones and use of Proceeds • First commercial PoNS (4.0) device design and manufacturing with Ximedica • Complete Phase 1B by Q2 calendar 2014 • Complete Phase 2 by Q3, calendar 2014 • Complete Phase 3-5 by December 31, 2014 • Clinical Trial for FDA approval in TBI • Interim data from UW pilot November 2014 will instruct registration trial design • Registration clinical trial by January 30, 2015 • Complete trial Q1, 2016 • Submit FDA filing Q2, 2016 • Obtain approval Q3, 2016 14 www.heliusmedical.com | CSNX: HSM

  15. Milestones and use of Proceeds (cont.) • Retained Proskauer IP Firm to expand IP development • The PoNSTM device intellectual property is the subject of U.S. Patent Application 12/348,301 and Provisional Patent Application 61/019,061; 61/020,265 • Maximize claims in US though collaborative relationship with USPTO • Use combination of medical method and PoNS to generate new IP • Generate Army Deployment Plan • Ensure VA system PT infrastructure is created for maximum deployment efficiency • Create Physical Therapy Support Network • Develop partnership with national suppliers by June 2015 • Develop certification plan for PTCs by May 2015 • Develop home base compliance monitoring structure ready to deploy Q2, 2016 • Obtain CPT reimbursement code for device reimbursement Q1, 2017 • Develop International Regulatory Submission Package (Q1, 2015) • Drive submission to Health Canada on a parallel track to the US submission 15 www.heliusmedical.com | CSNX: HSM

  16. Potential Indications for PoNS Therapy Direct Evidence Preliminary Data Theoretical basis 17 www.heliusmedical.com | CSNX: HSM

  17. Market Opportunity • PoNS device + physical or other therapy potentially treats the symptoms of multiple brain disorders/trauma • Each Indication requires clinical trial (16 months and $2M of funding) 18 www.heliusmedical.com | CSNX: HSM

  18. Appendix

  19. Competitive Landscape 20 www.heliusmedical.com | CSNX: HSM

  20. US Medical Technology M&A under $750M 21 www.heliusmedical.com | CSNX: HSM

  21. THE TEAM Philippe Deschamps, President, Chief Executive Officer and Director Phil Deschamps offers extensive experience in pharmaceutical and Healthcare commercialization. The depth of his expertise stems from his 28 years in the Health Sciences industry half of which was spent at Bristol Myers Squibb and half on the service side as CEO GSW Worldwide, a leading healthcare commercialization company. In February 2012 he joined MediMedia Health, a marketing services company as CEO. In October 2013 became CEO of Helius Medical Technologies. Deschamps oversaw MediMedia Health Marketing Services business. He was responsible for the strategic development of the organization, nurturing their clients and developing new non personal Communication products and services for the Healthcare industry At GSW, Deschamps was President and CEO and was responsible for the GSW Worldwide operations which includes offices in the 15 major markets around the world with a turnover of $160M. He primarily consulted on global marketing and commercialization, new business model development for pharmaceutical, device and diagnostics companies. Before joining GSW Worldwide Deschamps served as director of neuroscience marketing at Bristol- Myers Squibb (BMS) in Princeton, N.J., where he participated on several pre-launch Global Marketing teams in the neuroscience and pain therapeutic areas. He also held several marketing positions in the neuroscience, pain and metabolic therapeutic areas throughout his career. Deschamps has a BSc. From the University of Ottawa in Canada. 22 www.heliusmedical.com | CSNX: HSM

  22. THE TEAM Jonathan Sackier, Chief Medical Officer Jonathan Sackier has over 30 years of healthcare experience. Trained in Britain as a surgeon & recruited to the USA in 1989 he helped lead the laparoscopic surgery revolution. As a Professor at George Washington University in Washington, DC, he founded, and funded the Washington Institute of Surgical Endoscopy, a center for education, research, innovation and technology transfer. He is Visiting Professor of Surgery and Medicine at the University of Virginia where he teaches pro bono and his activities in basic and clinical research funded by multiple grants have led to many publications, chapters and books. He has served multiple journals in editorial or reviewer functions, been involved in medical societies at the highest level and been honored for his work in many countries. 25 www.heliusmedical.com | CSNX: HSM

  23. THE TEAM Kurt Kaczmarek, Mitch Tyler, Yuri Danilov Board Directors, Inventors of PoNS Technology Drs Kaczmarek, Tyler and Danilov founded in 1992, the Tactile Communication & Neurorehabilitation Laboratory (TCNL). It is located at the University of Wisconsin-Madison. TCNL is a research center that uses the experience of many different areas of science to study the theory and application of applied neuroplasticity, the brain’s ability to reorganize in response to new information, needs, and pathways. Their research is aimed at developing solutions for sensory and motor disorders. The center has three core areas that form the backbone of their research:  neuromodulation, sensory substitution, and electrotactile stimulation. They are committed to enhancing the rehabilitation process. They envision a future with a faster and more complete rehabilitation from sensory and motor disorders. They strive to improve existing therapies and develop new ones for conditions, which, in the past, had few or no options. Based on the work of our founder Paul Bach-y-Rita, M.D., the originator of the line of our current research, we believe that neuroplasticity is at the heart of all successful neurorehabilitation. The PoNS device is a result of their efforts at discovering a means to induce the brains neuroplasiticy to enhance rehabilitative care. 23 www.heliusmedical.com | CSNX: HSM

  24. THE TEAM Montel Williams, Spokesperson, Personal User & Shareholder Montel Williams earned his media celebrity status as an inspirational Emmy Award winning television personality whom Americans invited into their homes for more than 17 years. He is a decorated former naval officer, inspirational speaker, author, entrepreneur and advocate for patients worldwide. Mr Williams is a personal user of the PoNS technology and is passionate about bringing this technology to market for the benefits of patients suffering from neurological symptoms In addition to Helius Medical Technologies, Mr. Williams has several business interest in HealthCare, Renewable Energy and Consumer Products. 24 www.heliusmedical.com | CSNX: HSM

  25. T: 267-756-7028 E: info@heliusmedical.com W: www.heliusmedical.com Helius Medical Technologies, Inc.  Suite 1980, 1075 West Georgia StreetVancouver, BC, Canada, V6E 3C9

More Related